Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Although the revision of drug prices had a negative impact on generic drug sales, sales increased due to the effects of sales promotion activities and other factors. Operating profit increased due to higher sales and the absence of the milestone payment associated with the start of the domestic clinical trial for DMX-200, which was recorded in the year-earlier period.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥32,395 million (YoY +3.7%) |
| Operating profit | ¥1,743 million (YoY +39.7%) |
| Ordinary income | ¥1,434 million (YoY +26.8%) |
| Profit attributable to owners of the parent | ¥1,041 million (YoY +25.2%) |
| Net income per share | ¥122.03 |
| Equity ratio | End of the current fiscal period 40.1 / End of previous period 38.8 |
| Total assets | ¥91,284 million |
| Net assets | ¥36,639 million |
| Cash flows from operating activities | ¥7,719 million |
| Cash flows from investing activities | ¥-1,259 million |
| Cash flows from financing activities | ¥-5,558 million |
| Cash and cash equivalents at end of period | ¥5,748 million |
| Full-year earnings forecast | Net Sales ¥64,800 million (YoY +4.0%) / Operating profit ¥2,400 million (YoY -9.1%) / Ordinary income ¥1,800 million (YoY -23.4%) / Net income ¥1,500 million (YoY -25.4%) |
| Revision to Earnings Forecast | Not disclosed → Net Sales 64,800 / Operating profit 2,400 / Ordinary income 1,800 / Net income 1,500 |
| Annual Dividend Forecast | ¥90 → ¥91 |
| Depreciation and amortization | ¥1,313 million |
| Breakdown of extraordinary income (loss) | Interim period Extraordinary income No / Extraordinary loss None (total extraordinary losses: —) / Previous interim period Extraordinary income No / Extraordinary loss Loss on sale of investment securities ¥26 million / Impairment Losses on Investment Securities ¥1 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (for media representatives) |
| Issued Shares at Period-End | 9,451,169 |
| Treasury Shares at Period-End | 916,086 |
| Factors Behind Changes in Business Performance | Although the revision of drug prices had a negative impact on generic drug sales, sales increased due to the effects of sales promotion activities and other factors. Operating profit increased due to higher sales and the absence of the milestone payment associated with the start of the domestic clinical trial for DMX-200, which was recorded in the year-earlier period. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the revision of drug prices had a negative impact on generic drug sales, sales increased due to the effects of sales promotion activities and other factors. Operating profit increased due to higher sales and the absence in the current interim period of the milestone payment associated with the start of the domestic clinical trial for DMX-200, which was recorded in the year-earlier interim period. The company states that details of the reasons for revising the full-year forecast are provided in a separately released document.